bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.10.26.684652

BLOSUM Is All You Learn - Generative Antibody Models Reflect Evolutionary Priors

Abstract

Generative models have emerged as powerful tools for antibody sequence design, with recent studies demonstrating that log-likelihood scores from these models can correlate with binding affinity and potentially serve as effective ranking metrics. This raises a fundamental question: why should log-likelihood scores from generative models correlate with binding affinity? In this work, we investigate the biochemical basis of these model-derived log-likelihoods by comparing them with classical evolutionary similarity metrics. We find that BLOSUM similarity scores between designed and parental antibody sequences correlate strongly with measured binding affinity--on par with the predictive performance of a state-of-the-art diffusion-based generative model. Moreover, these BLOSUM scores also align closely with log-likelihoods from multiple generative models, suggesting that such models may be implicitly learning evolutionary priors encoded in substitution matrices. When computed with respect to a known binder, both BLO-SUM scores and log-likelihoods act as approximate measures of sequence distance from that reference. As this distance increases, the likelihood of a candidate being a binder decreases, explaining the observed correlation between these scores and binding affinity. In contrast, similarity scores based on position weight matrices (PWMs) and position-specific scoring matrices (PSSMs), which do not rely on knowledge of the parental sequence, show weaker and less consistent alignment with binding affinity, with performance depending on the background sequence data. Additionally, using consensus sequences in place of parental sequences to compute BLOSUM scores largely eliminates the observed correlation with affinity, underscoring the context-specific nature of the correlations. These findings highlight the potential of interpretable, evolution-inspired metrics to complement generative modeling in anti-body design, offering insights into both model behavior and biological relevance.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ucar, T., Sormanni, P.. 2025-10-27. BLOSUM Is All You Learn - Generative Antibody Models Reflect Evolutionary Priors. https://doi.org/10.1101/2025.10.26.684652

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Engineering and characterisation of AAVS1 FRT cell lines for inducible and dose-dependent gene expression

Investigating biological function with high reproducibility requires the generation of stable cell lines that offer precise and inducible transgene expression. However, traditional methods often suffer from the limitations of random genomic integration, including unpredictable expression levels, leaky basal activity, and disruption of endogenous loci. To address these challenges, we engineered a versatile RPE1 cell line by integrating a TetOn3G-FRT cassette into the AAVS1 safe-harbour locus using CRISPR/Cas9(D10A) nickase. This platform utilises the Flp-FRT recombination system to facilitate rapid, site-specific "plug-and-play" insertion of transgenes, combined with the Tet-On 3G system for tight, dose-dependent expression control. The resulting RPE1 AAVS1 FRT8 line enables highly consistent transgene induction across independent clones, behaving as a monoclonal population. We highlight the importance of rigorous cell line characterisation through a multi-omics approach. Whole genome sequencing identified precise heterozygous integration at the target locus and de novo genomic duplications on other chromosomes. By integrating WGS with high-resolution proteomics and cell cycle analysis, we confirmed that these alterations did not significantly perturb cellular homeostasis or phenotypic fitness. This work establishes a robust and reliable platform for the efficient generation of inducible AAVS1 FRT stable cell lines, facilitating reproducible research in modern molecular biology.

bioengineering↗

Raman-probe-derived biomarkers account for cartilage composition, structure, and viscoelastic properties

Raman spectroscopy is an inelastic light scattering technique that reflects the vibrational modes of the biochemical building blocks of the major constituents that comprise the cartilage extracellular matrix (ECM): glycosaminoglycans (GAG), type-II collagen (COL), and water. We investigated whether ECM-specific biomarkers measured with our recently developed arthroscopy-compatible Raman needle probe characterize the functional viscoelastic properties of articular cartilage explants. Equine osteochondral explants were harvested from high-load (femoral condyle) and low-load (intertrochlear groove) sites to evaluate Raman-derived biomarkers of cartilage structure and function. Viscoelastic material properties (equilibrium/dynamic modulus, phase shift) were determined by mechanical indentation. A computational fibril-reinforced biphasic material model was used to estimate the glycosaminoglycan-associated non-fibrillar-matrix modulus, the collagen-associated fibril-network modulus, and hydraulic permeability. Raman-derived biomarkers enabled evaluation of cartilage tissue composition and structure, accounting for 81% of the variation in GAG content, 53% of the variation in COL content, and 58% of the variation in COL anisotropy. Biomarkers also accounted for 81% of the variation in equilibrium modulus, 58% in dynamic modulus, and 51% in phase shift. For poroelastic properties, biomarkers accounted for 83% of the variation in non-fibrillar-matrix modulus, 25% of the variation in fibril-network modulus, and 34% of the variation in hydraulic permeability. Clinical Significance: Raman spectroscopy provides objective compositional biomarkers that account for viscoelastic material properties underlying articular cartilage function. These findings support its future use as an arthroscopic platform for objective assessment of cartilage injury, monitoring of disease progression, and evaluation of therapeutic interventions.

bioengineering↗

An adjuvant for in vivo CAR-T therapy potentiation against solid tumors

In vivo CAR-T therapy offers rapid and controllable T-cell engineering but has yet to achieve durable efficacy against solid tumors. Rather than focusing solely on CAR-T cells, we harness the intact immune system via an in vivo CAR-T adjuvant (iCTA). Composed of aluminum-manganese hydrogel, iCTA can form a spatially confined antigenic and immunostimulatory niche in-situ. By coupling controlled antigen exposure with STING-type I interferon signaling, iCTA not only recruited and reactivated CAR-T cells, but engage the CAR-negative immunocytes with enhanced dendritic-cell antigen presentation and mobilized endogenous antigen-specific T-cell responses. Combined with mRNA-LNP-mediated in vivo CAR-T generation, a single administration of iCTA increased CAR+ T-cell abundance in draining lymph nodes and blood by 2-fold. It also increased T and NK cell infiltration, established an IFNgamma-enriched tumor microenvironment, and reduced exhaustion-associated T-cell states. iCTA improved tumor regression and survival, establishing an adjuvant strategy to enhance in vivo CAR-T therapy.

bioengineering↗